BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 15817595)

  • 1. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
    Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
    Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
    J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
    Scott LJ; Keam SJ
    Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Hozumi Y; Suemasu K; Takei H; Aihara T; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Ann Oncol; 2011 Aug; 22(8):1777-82. PubMed ID: 21285133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
    Lu HH; Li Q; Xu BH; Zhang P; Yuan P; Wang JY; Cai RG
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):520-5. PubMed ID: 22093630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Livingston RB; Davidson NE; Perez EA; Chavarri-Guerra Y; Cameron DA; Pritchard KI; Whelan T; Shepherd LE; Tu D
    Ann Oncol; 2013 Feb; 24(2):355-361. PubMed ID: 23028039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M; Thürlimann B
    Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
    Jin H; Tu D; Zhao N; Shepherd LE; Goss PE
    J Clin Oncol; 2012 Mar; 30(7):718-21. PubMed ID: 22042967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.